Benign Breast Disease: Toward Molecular Prediction of Breast Cancer Risk
Abstract
Optimal early detection and prevention strategies for breast cancer are predicated on the health professional's ability to identify individuals at significantly increased risk for this disease. The purpose of this research is to bring molecular risk prediction for breast cancer into the clinical arena. This will require progress on three fronts of scientific endeavor: (1) establishment of a tissue repository of benign breast disease; (2) assessment of potential biomarkers of risk in this tissue set; and (3) discovery of new, potentially relevant biomarkers of risk. The authors have made significant progress on these aims. Their current cohort comprises 9,376 women, 758 (8%) of whom have been diagnosed with breast cancer since the time of their benign biopsy. They have established a tissue repository of benign breast tissue and have collected the subsequent breast cancers for 646 out of 758 (85%) of the cases. They have assessed the significance of benign histology in predicting the risk of future breast cancer, examining in detail the role of proliferative disease, atypia, papillomas, radial scars, and involution. They also have explored the link between centrosome amplification and COX-2 and breast cancer outcomes. This coming year, they will be focusing on additional molecular markers and genetic profiling.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2006
- Accession Number
- ADA457047
Entities
People
- Lynn C. Hartmann
Organizations
- Mayo Clinic